The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Savara Inc(NASDAQ:SVRA) 
Savara Inc. operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Aus...
Website: http://www.savarapharma.com
Founded: 1995
Full Time Employees: 36
Sector: Healthcare
Industry: Biotechnology
Savara Days Payable Outstanding ttm (DPO)
Savara Days Receivable Outstanding ttm (DSO)
Savara Days Inventory Outstanding ttm (DIO)
Savara Op Cashflow Per Share ttm
Savara Free Cashflow Per Share ttm
Savara Cash Per Share ttm
Savara P/S ratio ttm
Savara (GAAP) P/E ratio ttm
Savara P/B ratio ttm
No extra charts and metrics for this ticker.